Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GVGH altSonflex1-2-3 Shigella vaccine safety and immunogenicity study in adults, children, and infants
PACTR202208635693932Phase 2Recruiting
- Sponsor
- GSK
- Start
- Oct 2021
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 2 trial of GVGH altSonflex1-2-3 vaccine in shigellosis (18 arms), sponsored by GSK. Started Oct 2021; status: recruiting.
02
Drugs
GVGH altSonflex1-2-3 vaccine
03
Conditions
shigellosis
Beyond the preview
Go deeper on PACTR202208635693932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202208635693932.